Jamkas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-11-2024
- Paid Up Capital ₹ 0.10 M
as on 29-11-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 25.00 Cr
as on 29-11-2024
- Revenue -100.00%
(FY 2024)
- Profit -100.00%
(FY 2024)
- Ebitda
- Net Worth -4.89%
(FY 2024)
- Total Assets 691.01%
(FY 2024)
About Jamkas Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹25.00 Cr.
Vaneet Jain, Rupali Singla, Sayam Mittal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239HR2021PTC096279
- Company No.
096279
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jul 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jamkas Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaneet Jain  | Director | 13-Jul-2021 | Current |
| Rupali Singla | Director | 13-Jul-2021 | Current |
| Sayam Mittal | Director | 08-Jan-2024 | Current |
| Rakesh Kumar | Director | 15-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Jamkas Pharmaceuticals.
Jamkas Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 100% decrease in profit. The company's net worth dipped by a decrease of 4.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Jamkas Pharmaceuticals?
Unlock access to Jamkas Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Novotropics Healthcare LimitedActive 9 months 27 days
Vaneet Jain and Rupali Singla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 12 Apr 2024 | ₹25.00 Cr | Open |
How Many Employees Work at Jamkas Pharmaceuticals?
Jamkas Pharmaceuticals has a workforce of 0 employees as of Nov 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jamkas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jamkas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
